Joan Mannick MD
Job title: Co-Founder and Chief Medical Officer
Dr. Mannick is Co-Founder and Chief Medical Officer of resTORbio, a clinical stage biotechnology company that is developing medicines targeting cellular pathways that underlie aging-related diseases. The lead program is targeting the TORC1 pathway to improve immune function and decrease respiratory tract infections in the elderly.
Prior to joining resTORbio, Dr. Mannick was an Executive Director in the New Indications Discovery Unit of the Novartis Institutes of Biomedical Research. Prior to joining Novartis in 2010, Dr. Mannick was a Medical Director at Genzyme working in multiple therapeutic areas. Prior to Genzyme, Dr. Mannick was a faculty member at Harvard Medical School and University of Massachusetts Medical School. Her NIH-sponsored laboratory focused on the role of protein S-nitrosylation in physiology and pathophysiology.
Dr. Mannick received her A.B. from Harvard College and her M.D. from Harvard Medical School. She completed her residency in Internal Medicine at Brigham and Women’s Hospital and an Infectious Disease fellowship as part of the Harvard Combined Infectious Disease Program.
TORC1 Inhibition as an Immunotherapy to Decrease Respiratory Tract Infections in the Elderly 3:15 pm
Discussing the role of mTOR in aging Overviewing resTORbio’s TORC1 inhibitors Reviewing of Phase 2 clinical trials analyzing the effects of TORC1 inhibitors on immune function and respiratory tract infection rates in elderly subjectsRead more
day: Day Two